Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.
The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.
The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。